Fulgent Genetics (NASDAQ:FLGT – Get Ranking) up to date its FY22 earnings steerage on Monday. The corporate offered EPS steerage of $5.60 for the interval, in comparison with the consensus EPS estimate of $5.80. The corporate issued income steerage of $611 million, in comparison with the consensus income estimate of $623.67 million. Fulgent Genetics additionally up to date its FY 2022 steerage to $5.60-$5.60 EPS.
Analyst Scores Adjustments
Quite a lot of equities analysts have just lately commented on the corporate. TheStreet lower Fulgent Genetics from a b- ranking to a c+ ranking in a report on Thursday, July twenty eighth. StockNews.com started protection on Fulgent Genetics in a analysis notice on Wednesday, October twelfth. They set a maintain ranking for the corporate. Lastly, Credit score Suisse Group assumed protection on Fulgent Genetics in a analysis notice on Wednesday, August twenty fourth. They set an outperform ranking and a $65.00 worth goal for the corporate.
Fulgent Genetics Buying and selling Down 6.5 %
Shares of FLGT traded down $2.46 throughout buying and selling hours on Monday, hitting $35.52. The corporate had a buying and selling quantity of 844,816 shares, in comparison with its common quantity of 371,835. The corporate has a market capitalization of $1.08 billion, a PE ratio of two.83 and a beta of 1.54. Fulgent Genetics has a one 12 months low of $32.19 and a one 12 months excessive of $109.55. The corporate’s fifty day transferring common worth is $39.51 and its two-hundred day transferring common worth is $49.18.
Fulgent Genetics (NASDAQ:FLGT – Get Ranking) final introduced its earnings outcomes on Thursday, August 4th. The corporate reported $0.59 earnings per share for the quarter, hitting the consensus estimate of $0.59. Fulgent Genetics had a return on fairness of 33.04% and a web margin of 42.41%. The agency had income of $125.30 million for the quarter, in comparison with the consensus estimate of $122.70 million. Throughout the identical interval within the earlier 12 months, the enterprise earned $2.47 EPS. The agency’s income for the quarter was down 18.4% on a year-over-year foundation. Analysts forecast that Fulgent Genetics will put up 5.26 earnings per share for the present 12 months.
Insider Shopping for and Promoting
In associated information, CFO Paul Kim bought 662 shares of the enterprise’s inventory in a transaction on Tuesday, September sixth. The inventory was bought at a median worth of $41.39, for a complete transaction of $27,400.18. Following the transaction, the chief monetary officer now straight owns 149,507 shares within the firm, valued at roughly $6,188,094.73. The sale was disclosed in a doc filed with the SEC, which could be accessed by this hyperlink. In different Fulgent Genetics information, CFO Paul Kim bought 662 shares of the enterprise’s inventory in a transaction dated Tuesday, September sixth. The inventory was bought at a median worth of $41.39, for a complete transaction of $27,400.18. Following the sale, the chief monetary officer now owns 149,507 shares within the firm, valued at roughly $6,188,094.73. The transaction was disclosed in a doc filed with the SEC, which could be accessed by the SEC web site. Additionally, COO Jian Xie bought 675 shares of the enterprise’s inventory in a transaction dated Tuesday, August thirtieth. The shares had been bought at a median worth of $44.18, for a complete worth of $29,821.50. Following the sale, the chief working officer now owns 309,729 shares within the firm, valued at roughly $13,683,827.22. The disclosure for this sale could be discovered right here. 29.50% of the inventory is owned by firm insiders.
Institutional Buying and selling of Fulgent Genetics
Hedge funds have just lately modified their holdings of the inventory. Geneos Wealth Administration Inc. raised its holdings in Fulgent Genetics by 416.8% within the 1st quarter. Geneos Wealth Administration Inc. now owns 491 shares of the corporate’s inventory value $30,000 after buying an extra 396 shares through the interval. Value T Rowe Associates Inc. MD raised its holdings in shares of Fulgent Genetics by 13.4% through the second quarter. Value T Rowe Associates Inc. MD now owns 5,253 shares of the corporate’s inventory valued at $286,000 after buying an extra 620 shares over the last quarter. Graham Capital Administration L.P. acquired a brand new place in shares of Fulgent Genetics through the first quarter valued at roughly $294,000. Hsbc Holdings PLC grew its place in shares of Fulgent Genetics by 48.0% within the first quarter. Hsbc Holdings PLC now owns 5,652 shares of the corporate’s inventory valued at $350,000 after buying an extra 1,833 shares within the final quarter. Lastly, Financial institution of Montreal Can grew its place in shares of Fulgent Genetics by 7.6% within the first quarter. Financial institution of Montreal Can now owns 6,551 shares of the corporate’s inventory valued at $410,000 after buying an extra 461 shares within the final quarter. Hedge funds and different institutional buyers personal 43.22% of the corporate’s inventory.
Fulgent Genetics Firm Profile
Fulgent Genetics, Inc, along with its subsidiaries, supplies COVID-19, molecular diagnostic, and genetic testing providers to physicians and sufferers in america and internationally. The corporate provides genetic exams comprising Focus and Complete oncology panels exams; Beacon provider screening panels check for inherited circumstances; strong tumor molecular profiling for somatic most cancers testing; speedy entire genome testing for kids in NICU and PICU; new child genetic evaluation panel; single front-line check to detect ataxia-related variants and repeat expansions by sequencing; image genetics, a patient-initiated genetic testing; entire exome and medical exome panel exams; entire genome, mutation, and repeat enlargement testing providers, in addition to analysis service exams.
This on the spot information alert was generated by narrative science expertise and monetary information from MarketBeat with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you contemplate Fulgent Genetics, you will need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Fulgent Genetics wasn’t on the record.
Whereas Fulgent Genetics at present has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.